BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

...Ronny Gal, a senior analyst at Sanford Bernstein. “This is a hopeful time for biosimilars,” Gal...
...hockey stick is getting to the angle--revenue, market share and profits are all going up.” Gal...
...Collectively, the three biosimilars have 24% of the pegfilgrastim market, according to IQVIA data that Gal...
BioCentury | Aug 21, 2019
Distillery Therapeutics

LGALS3 identified as Huntington disease target

...as three LGALS3 inhibitors in preclinical testing: Gal-200 for ophthalmological disorders, Gal-300 for NASH and Gal-400...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | Aug 29, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Malaria In vitro , cell culture and mouse studies identified asparagine ethylenediamine-based inhibitors of Plasmodium falciparum proteasome subunit β type 5 that could help treat malarial infection. Screening of a library of tool compound proteasome...
BioCentury | Mar 31, 2017
Company News

Agalimmune, BioLineRx deal

...slated to begin clinical testing to treat solid tumors in 1H18. AGI-134 comprises glycolipids expressing alpha-gal...
BioCentury | Jan 11, 2017
Distillery Therapeutics

Transplant

INDICATION: Graft rejection; heart transplant rejection Mouse studies identified a dipeptide inhibitor of PSMB8 that could help prevent skin and heart transplant rejection. Chemical synthesis and testing in in vitro activity assays of dipeptides yielded...
BioCentury | Nov 4, 2016
Emerging Company Profile

Exploiting alpha-GAL

...compounds insert themselves into surrounding cell membranes, leaving alpha-GAL epitopes exposed to attract anti-GAL antibodies. Anti-GAL...
...then destroyed through antibody-dependent cellular toxicity (ADCC) and complement-mediated lysis. The interaction between anti-GAL and alpha-GAL...
...region of anti-GAL binds to Fc receptors on APCs, causing the APCs to internalize the alpha-GAL-coated...
BioCentury | May 12, 2016
Distillery Therapeutics

Therapeutics: ST6 β-galactoside α-2,6-sialyltransferase 1 (ST6GAL1); ST6GAL2

Autoimmune disease INDICATION: Rheumatoid arthritis (RA) Mouse studies suggest enhancing sialylation of autoantibodies could help treat RA. Levels of sialylation on RA autoantigen-specific and total IgG Fc were lower in sera from RA patients and...
BioCentury | Apr 4, 2016
Emerging Company Profile

Sugar-coated bugs

...comprise an aptamer that targets a species-specific epitope on bacteria conjugated to the sugar galactose-alpha-1,3-galactosyl-beta-1,4-N-acetyl-glucosamine (alpha-GAL...
...the target bacteria, leaving them coated in the sugar. The sugar attracts pre-existing antibodies against alpha-GAL...
...of mechanisms including complement-mediated lysis and antibody-dependent cellular cytotoxicity (ADCC). According to Westby, antibodies against alpha-GAL...
BioCentury | Sep 24, 2015
Distillery Therapeutics

Therapeutics: ST3 β-galactoside α-2,3-sialyltransferase 4 (ST3GAL4)

Gastrointestinal disease INDICATION: Colitis Mouse studies suggest inhibiting ST3GAL4 or sialidases to limit intestinal growth of Escherichia coli could help treat colitis. In normal mice, ST3GAL4 knockout decreased intestinal numbers of E. coli compared with...
Items per page:
1 - 10 of 198